Novavax Inc Update Call Transcript
Good day, and welcome to the Novavax COVID-19 vaccine Data Review Conference Call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Silvia Taylor, Senior VP of Global Corporate Affairs and Investor Relations. Please go ahead.
Good evening, everyone, and thank you to all of you who have joined us for today's call to discuss Novavax' initial Omicron cross-reactivity data from our COVID-19 booster and adolescent studies. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.
Please also note that we have posted the slides that we are using during this evening's call at novavax.com/events.
Joining me today for discussion and a Q&A period are Stan Erck, President and CEO; Dr. Filip Dubovsky, Chief Medical Officer; Dr. Greg Glenn, President of R&D; and John Trizzino,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |